A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
about
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancerMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionAberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartmentsInhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy.Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.Ubiquitination-dependent regulation of signaling receptors in cancer.Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferationEpidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabDiverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis.Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.17AAG-induced internalisation of HER2-specific Affibody molecules.Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
P2860
Q28264693-06D0367E-889E-4A89-80FF-622AB680B6FBQ28829301-E670D2E3-79BF-48E7-AFAE-1409883F9269Q30931456-408F3365-5E3F-420B-8C01-A220D6625AFFQ31107044-582E9CE4-19CD-4FBC-86FA-51B6BB503A69Q33576337-9742426F-BF60-47E5-B528-8905911BB290Q33686380-845DCA35-B790-47E1-9EA8-CF0D10B384A8Q33765280-FBA9DECD-EF38-437B-9EE1-677A487DD182Q33820676-AD37278B-F31F-47BD-8972-1C3CA172256CQ34365210-25E7C954-8CDF-41D2-93A6-EC4CF46C98A0Q34380963-B642DEB1-A018-4F54-B1C4-D49C00CD0E8BQ34430965-93A8BFB1-3993-482E-8AE4-454ED1060231Q34616517-EA28ADEB-1EDE-45BA-8485-109221ADE2A3Q35602561-088E33CB-4DFC-4F5F-AC27-A9F948EAA066Q35624814-B0AA6EA9-E186-419F-9171-26E4F79D6852Q35899955-6FD448D1-6480-4B76-AC8E-924003F6B298Q36062148-A88E6AF0-94AB-4BF0-9D9B-8170D28D12ACQ36680209-41F2162C-F3E3-489B-9CEA-3722BEAF4833Q36782465-EE488151-B942-40EA-90E1-8B831CC0A23EQ37148772-180F64CB-7358-414E-A72F-64BA3E60B56AQ38173991-6AE189D2-8F5F-400A-A6E6-24B3C60FE6D5Q39448675-CD136D6F-8BAB-437F-9AA3-12D07EC35B8AQ41197997-140562A8-E7C3-4744-BBA3-7B8F253A8423Q41773399-3601F996-9E77-468E-9824-4E6C847AD8C2Q52714930-E0B03487-424C-4976-935E-4DC79E8F60B3
P2860
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@en
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@nl
type
label
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@en
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@nl
prefLabel
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@en
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@nl
P2093
P2860
P356
P1476
A combination of Trastuzumab a ...... xpressing breast cancer cells.
@en
P2093
Alagarsamy Lakku-Reddi
Cesar Ortega-Cava
Hamid Band
Manjari Dimri
Mayumi Naramura
Mitra Bhattacharyya
Robert J Clubb
Srikumar M Raja
Vimla Band
P2860
P304
P356
10.4161/CBT.7.10.6585
P577
2008-10-09T00:00:00Z